Generic Name Pimecrolimus
Bangla Name পিমেক্রোলিমাস
Available brands 1

Introduction

Pimecrolimus is an immunomodulating agent & currently available as a topical cream used in the treatment of atopic dermatitis (eczema).

Uses

Pimecrolimus is a topical calcineurin inhibitor used in the treatment of mild-moderate atopic dermatitis who are not candidates for other types of therapy due to previous lack of response or other reasons.

For treatment of mild to moderate atopic dermatitis.

Associated Conditions

  • Vitiligo
  • Intertriginous psoriasis
  • Mild Atopic dermatitis
  • Moderate Atopic dermatitis
  • Refractory Atopic dermatitis

Pharmacodynamics

Pimecrolimus is a chemical that is used to treat atopic dermatitis (eczema). Atopic dermatitis is a skin condition characterized by redness, itching, scaling and inflammation of the skin. The cause of atopic dermatitis is not known; however, scientists believe that it may be due to activation of the immune system by various environmental or emotional triggers. Scientists do not know exactly how pimecrolimus reduces the manifestations of atopic dermatitis, but pimecrolimus reduces the action of T-cells and mast cells which are part of the immune system and contribute to responses of the immune system. Pimecrolimus prevents the activation of T-cells by blocking the effects of chemicals (cytokines) released by the body that stimulate T-cells. Pimecrolimus also reduces the ability of mast cells to release chemicals that promote inflammation.

Mechanism of Action

Pimecrolimus binds with high affinity to macrophilin-12 (FKBP-12) and inhibits the calcium-dependent phosphatase, calcineurin. As a consequence, it inhibits T cell activation by blocking the transcription of early cytokines. In particular, pimecrolimus inhibits at nanomolar concentrations Interleukin-2 and interferon gamma (Th1-type) and Interleukin-4 and Interleukin-10 (Th2-type) cytokine synthesis in human T cells. Also, pimecrolimus prevents the release of inflammatory cytokines and mediators from mast cells in vitro after stimulation by antigen/lgE.

Absorption

Because of the low systemic absorption of pimecrolimus following topical application the calculation of standard pharmacokinetic measures such as AUC, Cmax, half-life, etc. cannot be reliably done.

Protein Binding

74%-87% (in vitro, bound to plasma proteins)

Route of Elimination

80% of the drug is excreted in the feces.

Toxicity

Side effects include burning sensation, irritation, pruritus, erythema, and skin infections, at the application site.

Food Interactions

No interactions found.

Dosage

Apply a thin layer of Pimecrolimus Cream, 1% to the affected skin twice daily. The patient should stop using Pimecrolimus Cream, 1% when signs and symptoms (e.g., itch, rash and redness) resolve and should be instructed on what actions to take if symptoms recur.

If signs and symptoms persist beyond 6 weeks, patients should be re-examined by their health care provider to confirm the diagnosis of atopic dermatitis.

Continuous long-term use of Pimecrolimus Cream, 1% should be avoided, and application should be limited to areas of involvement with atopic dermatitis

The safety of Pimecrolimus Cream, 1% under occlusion, which may promote systemic exposure, has not been evaluated. Avoid use of Pimecrolimus Cream, 1% with occlusive dressings.

Medical review

Last reviewed: 24 Jul 2026

Medically reviewed by:

This is general information, not personal medical advice. Consult a doctor before taking any medicine.

Taking medicines without doctor's advice can cause long-term problems.
Brand medicines containing Pimecrolimus